Cargando…
A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia
INTRODUCTION: Behavioural variant frontotemporal dementia (bvFTD) is a neurodegenerative disorder often neuropathologically associated with the accumulation of abnormally hyperphosphorylated tau, for which there is currently no disease-modifying treatment. Previous work by our group has shown sodium...
Autores principales: | Vivash, Lucy, Malpas, Charles B, Churilov, Leonid, Walterfang, Mark, Brodtmann, Amy, Piguet, Olivier, Ahmed, Rebekah M, Bush, Ashley I, Hovens, Christopher M, Kalincik, T, Darby, David, Velakoulis, Dennis, O'Brien, Terence J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670941/ https://www.ncbi.nlm.nih.gov/pubmed/33199422 http://dx.doi.org/10.1136/bmjopen-2020-040100 |
Ejemplares similares
-
A phase 1b open‐label study of sodium selenate as a disease‐modifying treatment for possible behavioral variant frontotemporal dementia
por: Vivash, Lucy, et al.
Publicado: (2022) -
Sodium selenate as a therapeutic for tauopathies: A hypothesis paper
por: Dilcher, Roxane, et al.
Publicado: (2022) -
Sodium selenate as a disease-modifying treatment for mild–moderate Alzheimer’s disease: an open-label extension study
por: Vivash, Lucy, et al.
Publicado: (2021) -
Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial
por: Vivash, Lucy, et al.
Publicado: (2021) -
Phase II randomised placebo-controlled trial of sodium selenate as a disease-modifying treatment in chronic drug-resistant temporal lobe epilepsy: the SeLECT study protocol
por: Vivash, Lucy, et al.
Publicado: (2023)